Background gsl v2
GSL brings superior science, unique products, and patented technologies to the improvement and development of cannabinoid medicines, products, and plant cultivation. Our areas of focus include: patented extraction, phytocannabinoid isolation and custom reformulation technologies; research and development expertise in plant science and product development; and specialized fertilizers, lighting and growing systems for cultivators.
We are a team of experienced business professionals, entrepreneurs, doctors, professors, researchers and administrators with a common goal: to drive innovation, better products, and better outcomes in the cannabinoid industry, from plant to patient and all stages in between.


Green Sky Labs Inc. (GSL) is a Canadian corporation with vertically integrated business lines focused on its unique extraction and isolation technologies to produce pure isolates such as CBD and THC from hemp and marijuana. GSL’s proprietary technologies allow the extraction and isolation of these isolates at significant cost advantage over current methods. GSL will be setting up its own operations as well as joint venture partnerships across several key jurisdictions to manufacture and distribute the extract and isolate products. 



Custom Formulations for Desired Therapeutic Outcomes
Custom formulations of cannabinoid compounds targeted to address specific medical indications.

Precise, Custom Formulations
Our Medicines in Development

Green Sky Pharma is prioritizing its research and development efforts in areas with the greatest scientific and commercial promise: immunology and inflammation, oncology, neurology, neuroscience and pain, and anxiety disorders. Through proprietary extraction and formulation technologies, Green Sky Pharma is developing cannabinoid medical solutions that will matter most to the people we serve.

For additional information please visit our website at

Rehan has over 20 years of experience in investment banking, entrepreneurship, and corporate finance. He has helped structure and fund a number of leading edge companies in the biotechnology and information technology space. He has been a guest speaker on finance at a variety of conferences and universities across Canada and internationally. Mr. Huda held various positions within the Canadian federal government including Senior Economist for the Department of Finance and Senior Analyst for the Natural Resources and Industry Departments. He was a recipient of the Canadian government’s Public Service Award of Excellence for his financial and economic analysis related to the awarding of operating licenses to wireless telecommunication service providers.
Sarwat has over 6 years of executive management leadership including working as the Chief Financial Officer of a full service Canadian investment brokerage. In addition to her operational management experience, Sarwat has extensive experience in completing investment banking due diligence and financings, financial reporting and regulatory compliance. Prior to this role, she worked within the Tax & Treasury department of GlaxoSmithKline Inc., has several years of audit and tax advisor experience with KPMG LLP in Toronto and has successfully completed Parts I & II of the CPA In-Depth Tax Course. Sarwat also has experience completing annual regulatory filings with the SEC through her role as consultant CFO for a US publicly listed healthcare company.
Robert Leaker has made a career out of leading start up operations. He has started up business lines in retail branching, mortgages, wealth and insurance for Meridian Credit Union and CIBC. Prior to banking, he worked in the Petro-chemical industry launching numerous innovations in the utility, wastewater treatment and refining processes before moving into retail franchise operations management for Petro Canada. With his diverse background in science, engineering, retail operations and financial services, he has the unique ability to build cross-functional teams of highly skilled professionals from sciences, business, finance and sales.
Paul is a Chartered Financial Analyst (CFA) and an MBA graduate from the Schulich School of Business. Formerly from the areas of Corporate Business Development and mergers and acquisitions at Sun Life, committed to help uncover new specialized markets and niche opportunities to grow the business.
Dr. Elizabeth Crump is a microbiologist with 18 years experience in fish pathogens and vaccine development, including 10 years in industry with 3 years as a Quality Assurance and Regulatory Affairs Manager for Pfizer. Responsible for QA review, inspection coordination and all communication with government regulatory agencies, Dr. Crump is experienced in navigating complex regulatory frameworks and upholding best-in-class quality standards.
Serge E. Vidalis is a retired Officer of the Royal Canadian Navy’s Special Operations branch where he served in various strategic and tactical positions in Canada and overseas. His distinguished public service career also included five years of service as a police officer in British Columbia and fulfilling several Board of Director duties on various justice committees and community boards. Serge’s work in strategic security, risk management and protective services span over 30 years, including the last 20 years as the President and CEO of several Canadian and US firms. Serge holds a Master of Arts degree in Conflict Analysis and Management, and is a doctoral scholar in the area of national security and counterterrorism.